Generic Forteo Availability

Forteo is a brand name of teriparatide, approved by the FDA in the following formulation(s):

FORTEO (teriparatide recombinant human - injectable;subcutaneous)

  • Manufacturer: LILLY
    Approval date: June 25, 2008
    Strength(s): 0.6MG/2.4ML (0.25MG/ML) [RLD]

Has a generic version of Forteo been approved?

No. There is currently no therapeutically equivalent version of Forteo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Forteo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Stabilized teriparatide solutions
    Patent 6,770,623
    Issued: August 3, 2004
    Inventor(s): Chin-Ming; Chang & Henry A.; Havel
    Assignee(s): Eli Lilly and Company
    A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Patent expiration dates:
    • December 8, 2018
      ✓ 
      Patent use: A METHOD OF TREATING OSTEOPOROSIS
      ✓ 
      Drug product
    • December 8, 2018
      ✓ 
      Patent use: FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
      ✓ 
      Drug product
  • Method of increasing bone toughness and stiffness and reducing fractures
    Patent 6,977,077
    Issued: December 20, 2005
    Inventor(s): Hock; Janet M. & Gaich; Gregory A. & Dere; Willard H.
    Assignee(s): Eli Lilly and Company
    The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracure, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
    Patent expiration dates:
    • August 19, 2019
      ✓ 
      Patent use: METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
    • August 19, 2019
      ✓ 
      Patent use: A METHOD OF TREATING OSTEOPOROSIS
    • August 19, 2019
      ✓ 
      Patent use: FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
  • Stabilized teriparatide solutions
    Patent 7,144,861
    Issued: December 5, 2006
    Inventor(s): Chang; Chin-Ming & Havel; Henry A.
    Assignee(s): Eli Lilly and Company
    A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1–34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Patent expiration dates:
    • December 8, 2018
      ✓ 
      Drug product
  • Method of increasing bone toughness and stiffness and reducing fractures
    Patent 7,163,684
    Issued: January 16, 2007
    Inventor(s): Gaich; Gregory A. & Dere; Willard H. & Hock; Janet M.
    Assignee(s): Eli Lilly and Company
    The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
    Patent expiration dates:
    • August 19, 2019
      ✓ 
      Patent use: METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
    • August 19, 2019
      ✓ 
      Patent use: METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
    • August 19, 2019
      ✓ 
      Patent use: FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
  • Method of reducing the risk of bone fracture
    Patent 7,351,414
    Issued: April 1, 2008
    Inventor(s): Gaich; Gregory A. & Dere; Willard H. & Hock; Janet M.
    Assignee(s): Eli Lilly and Company
    The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fractur and/or reduce the incidence of non-vertebral fracture.
    Patent expiration dates:
    • August 19, 2019
      ✓ 
      Patent use: METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
    • August 19, 2019
      ✓ 
      Patent use: METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
    • August 19, 2019
      ✓ 
      Patent use: TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
  • Stabilized teriparatide solutions
    Patent 7,550,434
    Issued: June 23, 2009
    Inventor(s): Chang; Chin-Ming & Havel; Henry A.
    Assignee(s): Eli Lilly and Company
    A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Patent expiration dates:
    • December 8, 2018
      ✓ 
      Patent use: A METHOD OF TREATING OSTEOPOROSIS
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)